Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aroa Biosurgery Ltd ( (AU:ARX) ) just unveiled an announcement.
Aroa Biosurgery Limited announced it will host a webinar to discuss its September quarterly results, featuring CEO Brian Ward and CFO James Agnew. This event signifies the company’s commitment to transparency and engagement with stakeholders, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.90 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
More about Aroa Biosurgery Ltd
Aroa Biosurgery is a company specializing in soft-tissue regeneration, focused on developing, manufacturing, and distributing medical and surgical products aimed at improving healing in complex wounds and soft tissue reconstruction. Their products are based on a proprietary extracellular matrix biomaterial derived from sheep forestomach, and they have a significant market presence in the United States through direct sales and partnerships.
Average Trading Volume: 208,484
Technical Sentiment Signal: Buy
Current Market Cap: A$227.7M
See more data about ARX stock on TipRanks’ Stock Analysis page.